Pharmaceuticals News and Research

RSS

FDA launches workshop to simplify orphan drug development

The U.S. Food and Drug Administration (FDA) has announced the launch of an orphan drug workshop series--an opportunity for biotechnology companies, pharmaceutical firms, academics and other interested parties to spend two days creating applications for orphan status designation, under the guidance of staff from FDA's Office of Orphan Products Development (OOPD).

9 Dec 2009

Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced

AVANIR Pharmaceuticals, Inc. today announced additional data from the subset of patients with amyotrophic lateral sclerosis (ALS) enrolled in the confirmatory Phase III STAR trial.

9 Dec 2009

More number of obese adults are turning to bariatric surgery as a last resort, says WHO

The obesity epidemic is a staggering public health problem and despite increased attention and education, the WHO still predicts the number of obese adults worldwide to increase from 400 million to 700 million between 2005 and 2015.

9 Dec 2009

Reid to meet this afternoon with Democrats on health care reform deal

"Senate Democrats plan to hold a special caucus on health care reform at 5 p.m. Wednesday to discuss a tentative deal on how to change the bill's public insurance option," Roll Call reports. "A group of 10 Democrats — five centrists and five liberals — agreed Tuesday night to send a set of proposals to the Congressional Budget Office for an official score, but the details have yet to be presented to all 60 Members of the Democratic Conference.

9 Dec 2009

Pacific Beach BioSciences signs licensing agreement with major pharmaceutical company

Pacific Beach BioSciences, Inc. today reported that it has granted non-exclusive rights to a large pharmaceutical company for the use of one of its anti-fungal compounds required for the manufacturing of a clinical stage product.

9 Dec 2009

New York cuts drug reimbursements, states trim tobacco prevention funding

The Associated Press: "States cut funding for state tobacco prevention programs more than 15 percent this year, pushing it further than ever below federally recommended levels, according to a report that a coalition of public health groups is releasing Wednesday.

9 Dec 2009

Drug makers attract scrutiny over cost and ads, but may benefit from overhaul

Drug makers came under scrutiny after the AARP published research recently showing their wholesale prices had increased by an average of 9.3 percent during the past year, offsetting the value of rebates the industry promised as part of a health care overhaul to help seniors pay for drugs.

9 Dec 2009

USPTO grants CyDex Pharmaceuticals patent for Captisol

CyDex Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to the company entitled “Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof.” This patent, along with other previously issued technology patents, will provide broader protection for CyDex’s Captisol® technology until 2028.

9 Dec 2009

Decision Resources reports increased uptake of TNF-alpha inhibitors for Crohn's disease

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that compared to last year's analysis of U.S. patient-level claims data, TNF-alpha inhibitors are being used more often to treat newly diagnosed patients suffering from Crohn's disease.

9 Dec 2009

NYSE Amex to delist Cortex Pharmaceuticals

Cortex Pharmaceuticals, Inc. announced that it has received notification from the NYSE Amex LLC indicating that, due to the Company’s non-compliance with certain continued listing standards as previously reported, the Exchange intends to delist the Company’s common stock from the NYSE Amex effective as of the close of business on Friday, December 11, 2009.

9 Dec 2009

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

Watson Pharmaceuticals, Inc. today announced that the results of an open-label extension of two Phase 3 studies, published in the December issue of the peer-reviewed journal Urology, demonstrate long-term safety and tolerability of RAPAFLO® (silodosin) for up to 52 weeks of treatment. RAPAFLO® is an effective and uniquely selective alpha blocker for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH), the number one reason patients visit urologists.

9 Dec 2009

Hi-Tech Pharmacal reports net sales of $40.9M for the quarter ended October 31, 2009

Hi-Tech Pharmacal Co., Inc. today reported results for the quarter ended October 31, 2009.

9 Dec 2009

Waters begins shipping its ground-breaking SYNAPT G2 Mass Spectrometer

Waters Corporation announced today that it has shipped the first units of its ground-breaking SYNAPT(TM) G2 Mass Spectrometer, first introduced at the 2009 American Society of Mass Spectrometry (ASMS) annual conference in Philadelphia in June.

9 Dec 2009

Spectrum Pharmaceuticals recognized as one of the Top Work Places in Orange County

Spectrum Pharmaceuticals (NasdaqGM: SPPI), a commercial stage biotechnology company with a primary focus in oncology, today announced that it has been ranked by the Orange County Register as one of Orange County’s Top Work Places for 2009.

9 Dec 2009

Particle Sciences expands High Potency Compound handling capabilities

Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, has further expanded their High Potency Compound (HPC) handling capabilities through a unique relationship with IES Engineers.

9 Dec 2009

Report on the community-acquired pneumonia drug market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the patent expiries of three blockbuster antibiotics -- levofloxacin, moxifloxacin and piperacillin/tazobactam -- will be the primary factors contributing to a decline of more than 15 percent in the community-acquired pneumonia drug market though 2018.

9 Dec 2009

New drug designed to stop cancer from spreading by preventing mitosis

TGen Clinical Research Services at Scottsdale Healthcare (TCRS) is the world's first clinical trials site for a new drug designed to halt cancer cell division.

9 Dec 2009

No co-pays for patients enrolled in AstraZeneca's Medicare Part D prescription savings program

AstraZeneca announced today that patients enrolled in the company's Medicare Part D prescription savings program will no longer pay co-pays for their medicines through the program.

9 Dec 2009

Depression drug TC-5214 earns USF its most lucrative patent royalties to date

A depression drug created and patented by a team of University of South Florida researchers is at the center of major deal between global pharmaceutical company AstraZeneca PLC and Targacept, Inc., earning the university its potentially most lucrative patent royalties to date.

9 Dec 2009

TGen and Scottsdale Healthcare test PHA-848125ac drug for thymic cancer

The Translational Genomics Research Institute (TGen) and Scottsdale Healthcare are testing a new drug specifically for thymic cancer based on early promising results at Scottsdale Healthcare.

9 Dec 2009

Pharmaceuticals News and Research

FDA launches workshop to simplify orphan drug development

Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced

More number of obese adults are turning to bariatric surgery as a last resort, says WHO

Reid to meet this afternoon with Democrats on health care reform deal

Pacific Beach BioSciences signs licensing agreement with major pharmaceutical company

New York cuts drug reimbursements, states trim tobacco prevention funding

Drug makers attract scrutiny over cost and ads, but may benefit from overhaul

USPTO grants CyDex Pharmaceuticals patent for Captisol

Decision Resources reports increased uptake of TNF-alpha inhibitors for Crohn's disease

NYSE Amex to delist Cortex Pharmaceuticals

Watson Pharmaceuticals' RAPAFLO demonstrates safety and tolerability in BPH treatment

Hi-Tech Pharmacal reports net sales of $40.9M for the quarter ended October 31, 2009

Waters begins shipping its ground-breaking SYNAPT G2 Mass Spectrometer

Spectrum Pharmaceuticals recognized as one of the Top Work Places in Orange County

Particle Sciences expands High Potency Compound handling capabilities

Report on the community-acquired pneumonia drug market

New drug designed to stop cancer from spreading by preventing mitosis

No co-pays for patients enrolled in AstraZeneca's Medicare Part D prescription savings program

Depression drug TC-5214 earns USF its most lucrative patent royalties to date

TGen and Scottsdale Healthcare test PHA-848125ac drug for thymic cancer

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence